Fi recalls two dog supplements over possible Salmonella risk

Fi has recalled two dog supplements because of possible Salmonella contamination, adding another entry to a busy late-summer stretch of animal health and pet product recalls. The affected products are Fi Calming Supplement for Dogs, 180 g, lot 26118, and Fi 8-in-1 Formula Supplement for Dogs, 180 g, lot 26159. According to the FDA-posted company announcement, the issue traces back to an ingredient supplied to Fi’s manufacturer, which has now suspended production while it investigates. (fda.gov)

The recall was announced by the company on September 3, 2026, and published by FDA on September 8, 2026. FDA’s animal recall archive shows the Fi action alongside several other recent pet product recalls in 2026, including notices involving Salmonella, Listeria monocytogenes, nutrient imbalances, and foreign material. That broader pattern underscores how quality and supplier controls remain a live issue across pet food and supplement categories, not just in finished diets. (fda.gov)

The recalled products were distributed directly to consumers and through Amazon and Chewy, widening the practical reach of the recall beyond specialty retail. FDA said consumers should stop using the affected lots, keep the container tightly sealed, and dispose of it in the trash. The agency also reiterated the dual risk profile: dogs can become ill after ingestion, and people can be exposed through handling contaminated product or contact with animal waste, particularly without careful handwashing. (fda.gov)

Clinically, the signs FDA listed for dogs include lethargy, diarrhea or bloody diarrhea, fever, vomiting, decreased appetite, and abdominal pain. Importantly for veterinary professionals, infected dogs may also be subclinical carriers, which means a supplement-related exposure could have implications for other animals in the household and for human family members. That makes history-taking especially important in GI cases where pet parents may not initially think to mention a daily supplement alongside food, treats, or chews. (fda.gov)

Industry coverage has largely mirrored the FDA notice, emphasizing that the trigger appears to be an upstream ingredient issue rather than a confirmed contamination finding in every finished unit. PetfoodIndustry reported that production has been suspended during the investigation, and Fi’s own supplement marketing has highlighted vet-formulated products and adherence to National Animal Supplement Council standards. That contrast is notable: even brands positioning supplements around safety and quality systems can still be vulnerable to supplier-linked contamination events. (petfoodindustry.com)

Why it matters: For veterinary professionals, this recall sits at the intersection of nutrition, infection control, and client communication. Teams may need to broaden recall screening questions to include supplements, especially in dogs presenting with acute enteric signs. There’s also a staff safety component: handling returned products, discussing cleanup of feces or vomit, and advising immunocompromised household members all fit within routine client education when Salmonella is involved. Because these products were sold online, practices may also see pet parents who purchased them outside traditional veterinary channels and may not realize a supplement falls under the same recall logic as food. (fda.gov)

A secondary takeaway is the growing complexity of the companion animal supplement market. Fi is better known in many circles for connected pet devices, but its current terms and product pages show a broader push into ingestible products. As more lifestyle, tech, and direct-to-consumer brands expand into supplements, veterinarians may increasingly field questions about products that sit outside the conventional prescription or therapeutic nutrition ecosystem. (fitracking.com)

What to watch: The key next steps are whether the investigation identifies the specific ingredient source, whether additional lots or products are added, and whether FDA later classifies or updates the recall status in its archive. In the near term, practices should expect client questions, possible mild GI case discussions, and the need for clear guidance on disposal, hygiene, and when to seek veterinary care. (fda.gov)